Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK6 | P43250 | 2/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.37 |
| ▸ | TUBB | P07437 | 2/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.37 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.37 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.37 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.37 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.37 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.37 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.37 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.37 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.37 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.37 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.37 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.37 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.37 |
| ▸ | ITK | Q08881 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6448919 | 0.88 | GRK6 (0.47) | GRK6NR1H2NR1H3PIM1TUBB4A | |
| SCHEMBL6450070 | 0.87 | GRK6 (0.47) | GRK6NR1H2NR1H3NPC1RAB9A | |
| SCHEMBL6450529 | 0.85 | GRK6 (0.46) | GRK6NR1H2NR1H3TUBB4ATUBB | |
| SCHEMBL6449668 | 0.81 | SMN1; SMN2 (0.55) | GRK6NR1H2NR1H3NPY5RNPC1 | |
| SCHEMBL7152896 | 0.81 | NR1H2 (0.60) | GRK6NR1H2NR1H3AURKANPY5R | |
| SCHEMBL6454610 | 0.74 | GAA (0.51) | GRK6NR1H2NR1H3NPC1RAB9A | |
| SCHEMBL6450029 | 0.74 | KDM4E (0.43) | NR1H2NR1H3TUBB4ATUBBTUBA3C | |
| SCHEMBL6448909 | 0.74 | GRK6 (0.49) | GRK6NR1H2NR1H3NPC1RAB9A | |
| SCHEMBL6448384 | 0.74 | IDO1 (0.41) | GRK6NR1H2NR1H3NPY5RNPC1 | |
| SCHEMBL6450017 | 0.73 | GRK6 (0.44) | GRK6NR1H2NR1H3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | GRK6 2654/4885NR1H2 34/4885NR1H3 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.